Legato Capital Management LLC Acquires 10,344 Shares of AxoGen, Inc. (NASDAQ:AXGN)

Legato Capital Management LLC increased its holdings in AxoGen, Inc. (NASDAQ:AXGN) by 42.8% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 34,524 shares of the medical equipment provider’s stock after purchasing an additional 10,344 shares during the period. Legato Capital Management LLC owned approximately 0.08% of AxoGen worth $569,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in AXGN. Quest Partners LLC grew its stake in shares of AxoGen by 23,066.7% in the 3rd quarter. Quest Partners LLC now owns 2,085 shares of the medical equipment provider’s stock valued at $29,000 after purchasing an additional 2,076 shares during the period. R Squared Ltd acquired a new stake in AxoGen in the 4th quarter valued at $30,000. nVerses Capital LLC acquired a new stake in AxoGen in the 3rd quarter valued at $56,000. Oppenheimer & Co. Inc. bought a new position in shares of AxoGen during the third quarter valued at $156,000. Finally, Quantbot Technologies LP bought a new position in shares of AxoGen during the third quarter valued at $165,000. Institutional investors and hedge funds own 80.29% of the company’s stock.

AxoGen Trading Down 0.1 %

Shares of AXGN opened at $18.13 on Friday. AxoGen, Inc. has a 52-week low of $5.55 and a 52-week high of $19.18. The company has a market cap of $797.87 million, a price-to-earnings ratio of -56.66 and a beta of 1.00. The company has a debt-to-equity ratio of 0.67, a quick ratio of 2.47 and a current ratio of 3.74. The stock has a fifty day moving average price of $16.92 and a two-hundred day moving average price of $14.37.

Wall Street Analysts Forecast Growth

Separately, Canaccord Genuity Group increased their target price on shares of AxoGen from $18.00 to $22.00 and gave the stock a “buy” rating in a research report on Monday, February 3rd.

About AxoGen

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.